KAI1/CD_(82)和MRP-1/CD_9在膀胱移行细胞癌中的表达及临床意义

Expression of KAI1/CD_(82) and MRP-1/CD_9 in transitional cell carcinoma of bladder

目的探讨肿瘤转移抑制基因编码蛋白KAI1/CD82和能动性相关蛋白-1(MRP-1/CD9)在膀胱移行细胞癌中的表达及临床意义。方法采用免疫组织化学SP法观察52例膀胱癌石蜡标本中和KAI1/CD82和MRP-1/CD9的表达情况,结合临床资料进行分析。结果膀胱癌组织中KAI1/CD82和MRP-1/CD9的阳性表达率分别为50%和61.5%。KAI1/CD82和MRP-1/CD9阳性表达率在复发肿瘤中均随病理分级升高而下降(P<0.05),但与临床分期无关(P>0.05)。KAI1/CD82和MRP-1/CD9和的阳性表达率有显著相关性(r=0.316,P<0.05)。结论KAI1/CD82和MRP-1/CD9的表达可能是判断膀胱癌生物学行为的重要指标。

[Objective] To investigate expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of the bladder （TCCB） and its clinical significance. [Methods] Immunohistochemistry was used to detect KAI1/CD82 and MRP-1/CD9 protein expression in 52 TCCB specimens. Correlations of the expression of KAI1/CD82 and MRP-1/ CD9 to clinicopathological factors were statistically analyzed. [Results] The positive rates of KAI1/CD82 and MRP- 1/CD9 in transitional cell carcinoma of the bladder were 50% and 61.5%, respectively. MRP-1/CD9 and KAI1/CD82 expression was significantly associated with the pathological grade of TCCB （P 〈0.05）, but no correlation was found between MRP-1/CD9 or KAI1/CD82 expression and clinical stage of TCCB（P 〉0.05）. Furthermore, MRP-1/CD9 and KAI1/CD82 were expressed at lower level in recurrent TCCB samples than that of non-recurrent samples （P 〈0.05）. Meanwhile, the correlation between KAI1/CD82 expression and MRP-1/CD9 expression was statistically significant（r= 0.316, P 〈0.05）. [Conclusions] KAI1/CD82 and MRP-1/CD9 may be important prognostic indicators and potentially useful for assessing the biological behaviors of transitional cell carcinoma of the bladder.